BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

956 related articles for article (PubMed ID: 22857268)

  • 41. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates.
    Radesic B; Tremellen K
    Hum Reprod; 2011 Dec; 26(12):3437-42. PubMed ID: 21997895
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger.
    Fatemi HM; Garcia-Velasco J
    Fertil Steril; 2015 Apr; 103(4):870-3. PubMed ID: 25724740
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders.
    Griffin D; Benadiva C; Kummer N; Budinetz T; Nulsen J; Engmann L
    Fertil Steril; 2012 Jun; 97(6):1316-20. PubMed ID: 22480822
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
    Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response.
    De Placido G; Mollo A; Clarizia R; Strina I; Conforti S; Alviggi C
    Fertil Steril; 2006 Jan; 85(1):247-50. PubMed ID: 16412769
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation?
    Kedem A; Tsur A; Haas J; Yerushalmi GM; Hourvitz A; Machtinger R; Orvieto R
    Fertil Steril; 2014 Jun; 101(6):1624-8. PubMed ID: 24680364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GnRH antagonist rescue of a long-protocol IVF cycle and GnRH agonist trigger to avoid ovarian hyperstimulation syndrome: three case reports.
    Martínez F; Rodríguez DB; Buxaderas R; Tur R; Mancini F; Coroleu B
    Fertil Steril; 2011 Jun; 95(7):2432.e17-9. PubMed ID: 21513932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients.
    Tehraninejad ES; Nasiri R; Rashidi B; Haghollahi F; Ataie M
    Arch Gynecol Obstet; 2010 Sep; 282(3):319-25. PubMed ID: 20379731
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type.
    Lambalk CB; Banga FR; Huirne JA; Toftager M; Pinborg A; Homburg R; van der Veen F; van Wely M
    Hum Reprod Update; 2017 Sep; 23(5):560-579. PubMed ID: 28903472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
    Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
    Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
    Itskovitz-Eldor J; Kol S; Mannaerts B
    Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF.
    Pu D; Wu J; Liu J
    Hum Reprod; 2011 Oct; 26(10):2742-9. PubMed ID: 21778283
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Protocol with GnRH-antagonist and ovulation trigger with GnRH-agonist in risk patients--a reliable method of prophylactic of OHSS].
    Kovachev E
    Akush Ginekol (Sofiia); 2008; 47(4):16-9. PubMed ID: 19227761
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Maternal and neonatal outcomes after gonadotropin-releasing hormone agonist trigger for final oocyte maturation in patients undergoing in vitro fertilization.
    Budinetz TH; Mann JS; Griffin DW; Benadiva CA; Nulsen JC; Engmann LL
    Fertil Steril; 2014 Sep; 102(3):753-8. PubMed ID: 24954776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GnRH agonist and antagonist protocols for stage I-II endometriosis and endometrioma in in vitro fertilization/intracytoplasmic sperm injection cycles.
    Pabuccu R; Onalan G; Kaya C
    Fertil Steril; 2007 Oct; 88(4):832-9. PubMed ID: 17428479
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates.
    Griffin D; Feinn R; Engmann L; Nulsen J; Budinetz T; Benadiva C
    Fertil Steril; 2014 Aug; 102(2):405-9. PubMed ID: 24842671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes.
    Zilberberg E; Haas J; Dar S; Kedem A; Machtinger R; Orvieto R
    Gynecol Endocrinol; 2015 Feb; 31(2):145-7. PubMed ID: 25385007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
    Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
    Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.